Beta-Blockers in Takotsubo Syndrome Study

Phase 4

Not yet recruiting

• Conditions: Takotsubo Cardiomyopathy; Beta-blockers; Echocardiography; Left Ventricular Function

• Registration Number: NCT06509074
• Lead Sponsor: Spanish Society of Cardiology

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2024-7-8
• Last Update Posted: 2 September 2024

Recruitment & Eligibility

• Status: Not yet recruiting
• Sex: All
• Target Recruitment: 200

Inclusion Criteria

Inclusion Criteria:<br><br> - Written informed consent.<br><br> - Diagnosis of TTS with exclusion of significant coronary artery disease (CAD) by<br> invasive coronary angiography<br><br>Exclusion Criteria:<br><br> - Patients diagnosed of TTS > 48 hours before.<br><br> - Persistent ccardiogenic shock or severe hemodynamic instability<br><br> - Persistent severe (>30 mmHg) intraventricular gradient<br><br> - Previous diagnosis of severe valvular or ventricular disease or prior myocardial<br> infarction secondary to atherosclerotic CAD<br><br> - Patients already receiving treatment with betablockers ()<br><br> - Absolute contraindication/indication for beta-blockers (**)<br><br> - Poor echocardiographic window<br><br> - Pregnant or breastfeeding women.<br><br> - Participation in another clinical trial.<br><br>() Betablockers at a therapeutic dose at the time of symptom´s onset. (**) Close ECG<br>monitoring required in patients with hypotension, bradycardia or cQT interval<br>prolongation

Exclusion Criteria

Not provided

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Wall motion score index

Secondary Outcome Measures

Name	Time	Method
Left ventricular ejection fraction;Global longitudinal strain;Delta (Change) in: wall motion score index, left ventricular ejection fraction, global longitudinal strain;Delta (Change) in: wall motion score index, left ventricular ejection fraction, global longitudinal strain;Combined clinical endpoint (death, stroke, recurrent TTS, heart failure, acute coronary syndrome, atrial fibrillation;Individual endpoints of the combined clinical endpoint Occurrence of death, stroke, recurrent TT, heart failure, acute coronary syndrome, atrial fibrillation will be analyzed and compared individually;Angina and quality of life status during daily life assessed in routine clinical practice